Agios Pharmaceuticals (NASDAQ:AGIO) Stock Crosses Below Two Hundred Day Moving Average – What’s Next?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s share price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $29.87 and traded as low as $27.75. Agios Pharmaceuticals shares last traded at $28.21, with a volume of 757,913 shares trading hands.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. JPMorgan Chase & Co. boosted their price objective on Agios Pharmaceuticals from $31.00 to $36.00 and gave the company a “neutral” rating in a report on Monday, April 6th. Truist Financial lowered their price objective on Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, April 30th. HC Wainwright lowered their price objective on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating for the company in a report on Monday, April 20th. The Goldman Sachs Group boosted their price objective on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a report on Wednesday, April 1st. Finally, Bank of America dropped their target price on shares of Agios Pharmaceuticals from $44.00 to $41.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $41.56.

Agios Pharmaceuticals Price Performance

The company has a market capitalization of $1.69 billion, a P/E ratio of -3.93 and a beta of 0.58. The company has a fifty day moving average price of $29.60 and a 200 day moving average price of $29.67.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, beating the consensus estimate of ($1.81) by $0.12. The company had revenue of $20.75 million during the quarter, compared to analyst estimates of $13.30 million. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The firm’s revenue for the quarter was up 137.7% compared to the same quarter last year. On average, equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.19 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider James William Burns sold 3,280 shares of Agios Pharmaceuticals stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $113,848.80. Following the sale, the insider owned 49,306 shares of the company’s stock, valued at $1,711,411.26. The trade was a 6.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Cecilia Jones sold 3,141 shares of Agios Pharmaceuticals stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $109,024.11. Following the sale, the chief financial officer directly owned 54,998 shares in the company, valued at $1,908,980.58. The trade was a 5.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 15,582 shares of company stock worth $520,405. 5.40% of the stock is owned by company insiders.

Institutional Trading of Agios Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Bellevue Group AG lifted its stake in shares of Agios Pharmaceuticals by 3.5% in the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock worth $149,110,000 after acquiring an additional 124,586 shares during the period. State Street Corp lifted its stake in shares of Agios Pharmaceuticals by 37.4% in the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after acquiring an additional 845,433 shares during the period. Erste Asset Management GmbH lifted its stake in shares of Agios Pharmaceuticals by 1.4% in the 4th quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock worth $76,343,000 after acquiring an additional 40,000 shares during the period. Wellington Management Group LLP lifted its stake in shares of Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock worth $99,203,000 after acquiring an additional 2,049,287 shares during the period. Finally, Commodore Capital LP boosted its stake in Agios Pharmaceuticals by 0.6% during the third quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock valued at $93,859,000 after buying an additional 13,287 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.